An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult male patients with Tourette Syndrome (TS)
Latest Information Update: 25 Apr 2024
At a glance
- Drugs Gemlapodect (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Acronyms Allevia; NOE-TTS-211
- Sponsors Noema Pharma
- 24 Apr 2024 This trial has been completed in Germany (Global end date: 3 Apr 2024).
- 21 Jun 2023 According to a Noema Pharma media release, company has completed this trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort.
- 05 Jan 2023 According to a Noema Pharma media release, trial has been completed in adult patients with Tourette Syndrome.